Drugmaker AbbVie Trims Profit Forecasts On IPR&D Expenses

Drugmaker AbbVie Trims Profit Forecasts On IPR&D Expenses

(Reuters) -AbbVie Inc on Wednesday lowered its full-year and first-quarter profit expectations, citing a $150 million hit from acquired in-process research and development (IPR&D) and milestone expenses. The drugmaker’s shares were down nearly 1% at $159.50 in extended trade. The company estimated first-quarter adjusted earnings to be between $2.31 and $2.41 per share from an…

Read More

Goldman Sachs fined $3 million by FINRA over mismarking short sale orders

NEW YORK (Reuters) – The Financial Industry Regulatory Authority, Wall Street’s self-funded watchdog, fined Goldman Sachs Inc $3 million on Tuesday for mistakenly marking some of its stock orders as “long” instead of “short”, and for trade reporting violations. From October 2015 to April 2018, Goldman mismarked around 60 million short sale orders totaling more…

Read More